maradona
Established Member
- Reaction score
- 0
It's over my bald brothahs, its over :sobbing: they killed the bastard :sobbing: they got him good. :sobbing:
This an excerpt from replicel's jan 30 update:
"The initial data from RepliCel's 6-month subject follow-up will be used in the Company's Investigational Medical Product Dossier (IMPD), which is presently being developed for a Phase IIb dose-ranging clinical trial of 100 patients that is expected to commence in fall 2012. The protocol will be submitted to the EMEA, FDA and Health Canada for review. A final decision on the location of the trial is pending.
This is the whole article:
January 30, 2012
VANCOUVER, BC – January 30, 2012 – RepliCel Life Sciences Inc. (the “Company†or “RepliCelâ€) (OTCBB: REPCF) is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.
To date, 17 of 19 subjects have had their six-month follow-up visit, during which time subjects had their overall health evaluated. This included subjective and objective assessment of verum and placebo injected sites and digital images were taken of the scalp and injection areas. The digital images will be used to assess any treatment response and any post-injection changes in scalp health compared to baseline and between the two treatment areas. The remaining two patients are scheduled to complete their follow-up visits before the end of March. Four patients will complete 12-month follow-up visits in that same time frame.
To date, no serious adverse events have been reported post injection in any of the 10 men and 9 women participating in the study.
The TS001-2009 study team will be performing a thorough review of the collected study data throughout the months of March and April 2012. Once complete, the treatment groups will be revealed (‘un-blinded’) to the data analysis team and the data will be analyzed. RepliCel remains on schedule to release the initial review of efficacy results in April 2012.
Subject efficacy at 6-months post injection is the first step in measuring a treatment response. All subjects will continue to participate in the post injection follow-up period of the study until August 2013 and a review of final safety and efficacy results will commence before the end of 2013. The continued follow-up period is a key component of the study to confirm treatment safety profile and response trends at 6, 12 and 24 months.
The initial data from RepliCel’s 6-month subject follow-up will be used in the Company’s Investigational Medical Product Dossier (IMPD), which is presently being developed for a Phase IIb dose-ranging clinical trial of 100 patients that is expected to commence in fall 2012. The protocol will be submitted to the EMEA, FDA and Health Canada for review. A final decision on the location of the trial is pending.
About RepliCel Life Sciences
The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair lossin men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past nine years by the Company’s recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.
For more information please contact:
Tammey George, Director of Communications
Telephone: 604-248-8696
tg@replicel.com
www.replicel.com
Anyways looks like good news to me but then they write something about these statements might not always happen due to other "circumstances" that may happen. :whistle:
This an excerpt from replicel's jan 30 update:
"The initial data from RepliCel's 6-month subject follow-up will be used in the Company's Investigational Medical Product Dossier (IMPD), which is presently being developed for a Phase IIb dose-ranging clinical trial of 100 patients that is expected to commence in fall 2012. The protocol will be submitted to the EMEA, FDA and Health Canada for review. A final decision on the location of the trial is pending.
This is the whole article:
January 30, 2012
VANCOUVER, BC – January 30, 2012 – RepliCel Life Sciences Inc. (the “Company†or “RepliCelâ€) (OTCBB: REPCF) is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.
To date, 17 of 19 subjects have had their six-month follow-up visit, during which time subjects had their overall health evaluated. This included subjective and objective assessment of verum and placebo injected sites and digital images were taken of the scalp and injection areas. The digital images will be used to assess any treatment response and any post-injection changes in scalp health compared to baseline and between the two treatment areas. The remaining two patients are scheduled to complete their follow-up visits before the end of March. Four patients will complete 12-month follow-up visits in that same time frame.
To date, no serious adverse events have been reported post injection in any of the 10 men and 9 women participating in the study.
The TS001-2009 study team will be performing a thorough review of the collected study data throughout the months of March and April 2012. Once complete, the treatment groups will be revealed (‘un-blinded’) to the data analysis team and the data will be analyzed. RepliCel remains on schedule to release the initial review of efficacy results in April 2012.
Subject efficacy at 6-months post injection is the first step in measuring a treatment response. All subjects will continue to participate in the post injection follow-up period of the study until August 2013 and a review of final safety and efficacy results will commence before the end of 2013. The continued follow-up period is a key component of the study to confirm treatment safety profile and response trends at 6, 12 and 24 months.
The initial data from RepliCel’s 6-month subject follow-up will be used in the Company’s Investigational Medical Product Dossier (IMPD), which is presently being developed for a Phase IIb dose-ranging clinical trial of 100 patients that is expected to commence in fall 2012. The protocol will be submitted to the EMEA, FDA and Health Canada for review. A final decision on the location of the trial is pending.
About RepliCel Life Sciences
The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair lossin men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past nine years by the Company’s recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.
For more information please contact:
Tammey George, Director of Communications
Telephone: 604-248-8696
tg@replicel.com
www.replicel.com
Anyways looks like good news to me but then they write something about these statements might not always happen due to other "circumstances" that may happen. :whistle:
unk: